- Home
- NATR vs CLLS Comparison
NATR vs CLLS Comparison
Compare NATR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATR
- CLLS
- Stock Information
- Founded
- NATR 1972
- CLLS 1999
- Country
- NATR United States
- CLLS France
- Employees
- NATR N/A
- CLLS N/A
- Industry
- NATR Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NATR Health Care
- CLLS Health Care
- Exchange
- NATR Nasdaq
- CLLS Nasdaq
- Market Cap
- NATR N/A
- CLLS 240.2M
- IPO Year
- NATR N/A
- CLLS 2007
- Fundamental
- Price
- NATR $15.00
- CLLS $1.57
- Analyst Decision
- NATR Strong Buy
- CLLS Buy
- Analyst Count
- NATR 2
- CLLS 3
- Target Price
- NATR $19.50
- CLLS $7.00
- AVG Volume (30 Days)
- NATR 47.1K
- CLLS 59.8K
- Earning Date
- NATR 11-07-2024
- CLLS 11-04-2024
- Dividend Yield
- NATR N/A
- CLLS N/A
- EPS Growth
- NATR 114.95
- CLLS N/A
- EPS
- NATR 0.88
- CLLS N/A
- Revenue
- NATR $445,095,000.00
- CLLS $36,042,000.00
- Revenue This Year
- NATR $2.07
- CLLS $271.02
- Revenue Next Year
- NATR $2.62
- CLLS $33.48
- P/E Ratio
- NATR $16.97
- CLLS N/A
- Revenue Growth
- NATR 1.36
- CLLS 46.96
- 52 Week Low
- NATR $10.81
- CLLS $1.53
- 52 Week High
- NATR $21.72
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- NATR 42.45
- CLLS 27.91
- Support Level
- NATR $14.90
- CLLS $1.85
- Resistance Level
- NATR $15.88
- CLLS $2.09
- Average True Range (ATR)
- NATR 0.62
- CLLS 0.09
- MACD
- NATR -0.21
- CLLS -0.04
- Stochastic Oscillator
- NATR 5.24
- CLLS 0.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.